Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q2 EPS of ($0.19), $0.03 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $25.3 million versus the consensus estimate of $26.1 million.

GUIDANCE:

Xeris Pharmaceuticals Inc. sees FY2022 revenue of $105-120 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.